Status: Recruiting
Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes.
Participants needed: 2,500
Trial details
Biological sex: AllType: InterventionalSponsor: University of California, San FranciscoUpdated: Jan 26, 2026Locations: 1
Eligibility criteria
Active RR-TB diagnosed at a study facility during the study period [+1]
Patient expects to relocate/move residence outside of the study region [+1]